Zhang Xiubin, Quint Jennifer K
National Heart and Lung Institute, Imperial College London, London, W12 0BZ, United Kingdom.
J Asthma Allergy. 2023 Sep 18;16:987-996. doi: 10.2147/JAA.S426227. eCollection 2023.
High short-acting β-agonist (SABA) use and/or inhaled corticosteroid (ICS) underuse are common and are associated with poor asthma outcomes. This study explored patients' and healthcare practitioners' (HCPs') perspectives to contextualize asthma treatment patterns observed in real-world studies.
Data were collected using online surveys from HCPs and people with asthma (≥18 years old with a confirmed asthma diagnosis of any severity) who had consented to research participation through the Clinical Practice Research Datalink. Data were analysed using descriptive statistics.
In total, 76 HCPs and 63 patients were invited to take part. Of 48 valid HCP responders, 54.2% (n=26) reported scheduling an annual asthma treatment review with their patients and 83.3% of general practitioners (n=40) had prescribed repeated inhalers at the patient's request. Of 47 valid patient responders, 57.4% (n=27) reported using their reliever (SABA) inhaler daily and 55.3% of patients (n=26) reported being prescribed a preventer inhaler. Of the total patient responders, 31.9% (n=15) reported that they never used their preventer inhaler. Consistent annual adherence with preventer inhalers was reported by 44.7% of all valid responders (n=21), while other patients admitted to using preventers intermittently.
SABA and ICS prescription patterns are driven by a combination of HCP and patient factors. Opportunities exist to improve asthma control and behaviours around inhaler use.
短效β受体激动剂（SABA）使用频繁和/或吸入性糖皮质激素（ICS）使用不足的情况很常见，且与哮喘不良预后相关。本研究探讨了患者和医疗从业者（HCP）的观点，以便将在现实世界研究中观察到的哮喘治疗模式置于具体情境中。
通过在线调查收集来自HCP以及哮喘患者（年龄≥18岁，确诊为任何严重程度的哮喘）的数据，这些患者已通过临床实践研究数据链同意参与研究。使用描述性统计方法分析数据。
总共邀请了76名HCP和63名患者参与。在48名有效的HCP受访者中，54.2%（n = 26）报告为其患者安排了年度哮喘治疗复查，83.3%的全科医生（n = 40）应患者要求开具了重复使用的吸入器。在47名有效的患者受访者中，57.4%（n = 27）报告每天使用缓解药物（SABA）吸入器，55.3%的患者（n = 26）报告被开具了预防性吸入器。在所有患者受访者中，31.9%（n = 15）报告他们从未使用过预防性吸入器。44.7%的所有有效受访者（n = 21）报告每年持续坚持使用预防性吸入器，而其他患者承认间歇性使用预防性药物。
SABA和ICS的处方模式是由HCP和患者因素共同驱动的。存在改善哮喘控制和吸入器使用行为的机会。
